Putting the “bio” in “biotherapeutics”/checkpoints for biosimilars/application of biosimilars

Juan V. Esplugues; Bruno Flamion; Lluis Puig

doi:10.1016/j.nhtm.2016.10.002

Putting the “bio” in “biotherapeutics”/checkpoints for biosimilars/application of biosimilars

Juan V. Esplugues, Bruno Flamion, Lluis Puig

URPHYM

Research output: Contribution to journal › Comment/debate › peer-review

Abstract

The number of biosimilar medicines on the market is steadily increasing, due, in part, to patent expiration of several top-selling biologic medicines. These three e-learning modules discuss the basic concepts behind biosimilar medicines and highlight key regulatory considerations when using biosimilar medicines in medical practice.

Original language	English
Pages (from-to)	161
Number of pages	1
Journal	New Horizons in Translational Medicine
Volume	3
Issue number	3-4
DOIs	https://doi.org/10.1016/j.nhtm.2016.10.002
Publication status	Published - 1 Dec 2016

Access to Document

10.1016/j.nhtm.2016.10.002

Cite this

@article{22d230533b914af5a197ac5422a7cbb4,

title = "Putting the “bio” in “biotherapeutics”/checkpoints for biosimilars/application of biosimilars",

abstract = "The number of biosimilar medicines on the market is steadily increasing, due, in part, to patent expiration of several top-selling biologic medicines. These three e-learning modules discuss the basic concepts behind biosimilar medicines and highlight key regulatory considerations when using biosimilar medicines in medical practice.",

author = "Esplugues, {Juan V.} and Bruno Flamion and Lluis Puig",

year = "2016",

month = dec,

day = "1",

doi = "10.1016/j.nhtm.2016.10.002",

language = "English",

volume = "3",

pages = "161",

journal = "New Horizons in Translational Medicine",

issn = "2307-5023",

publisher = "Elsevier",

number = "3-4",

}

TY - JOUR

T1 - Putting the “bio” in “biotherapeutics”/checkpoints for biosimilars/application of biosimilars

AU - Esplugues, Juan V.

AU - Flamion, Bruno

AU - Puig, Lluis

PY - 2016/12/1

Y1 - 2016/12/1

N2 - The number of biosimilar medicines on the market is steadily increasing, due, in part, to patent expiration of several top-selling biologic medicines. These three e-learning modules discuss the basic concepts behind biosimilar medicines and highlight key regulatory considerations when using biosimilar medicines in medical practice.

AB - The number of biosimilar medicines on the market is steadily increasing, due, in part, to patent expiration of several top-selling biologic medicines. These three e-learning modules discuss the basic concepts behind biosimilar medicines and highlight key regulatory considerations when using biosimilar medicines in medical practice.

UR - http://www.scopus.com/inward/record.url?scp=84994579983&partnerID=8YFLogxK

U2 - 10.1016/j.nhtm.2016.10.002

DO - 10.1016/j.nhtm.2016.10.002

M3 - Comment/debate

AN - SCOPUS:84994579983

SN - 2307-5023

VL - 3

SP - 161

JO - New Horizons in Translational Medicine

JF - New Horizons in Translational Medicine

IS - 3-4

ER -

Putting the “bio” in “biotherapeutics”/checkpoints for biosimilars/application of biosimilars

Abstract

Access to Document

Other files and links

Cite this